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Abstract
Background: Hypertension is one of the most important causes of end-stage renal disease, but it is unclear
whether elevated blood pressure (BP) also accelerates the gradual decline in the glomerular filtration rate (GFR)
seen in the general population with increasing age. The reason may be that most studies have considered only
baseline BP and not the effects of changes in BP, antihypertensive treatment and other determinants of GFR during
follow-up. Additionally, the use of GFR estimated from creatinine or cystatin C instead of measurements of GFR
may have biased the results because of influence from non-GFR related confounders. We studied the relationship
between BP and GFR decline using time-varying variables in a cohort representative of the general population
using measurements of GFR as iohexol clearance.
Methods: We included 1594 subjects aged 50 to 62 years without baseline diabetes, kidney-, or cardiovascular
disease in the Renal Iohexol-clearance Survey in Tromsø 6 (RENIS-T6). GFR, BP, antihypertensive medication and all
adjustment variables were ascertained at baseline, and at follow-up after a median observation time of 5.6 years in
1299 persons (81%). The relationship between GFR decline and BP was analyzed in linear mixed models.
Results: The mean (standard deviation) GFR decline rate was 0.95 (2.23) mL/min/year. The percentage of persons
with hypertension (systolic BP ≥ 140 mmHg, diastolic BP ≥ 90 mmHg or antihypertensive medication) increased from
42 to 52% between baseline and follow-up. In multivariable adjusted linear mixed models using time-varying
independent variables measured at baseline and follow-up, higher systolic and diastolic BP were associated with
slower GFR decline rates by 0.10 and 0.20 mL/min/year/10 mmHg, respectively (p < 0.05). The association was
stronger in persons on antihypertensive medication than in others (p < 0.05 for the interaction between BP and
antihypertensive medication).
Conclusions: In the medium-term, elevated BP is not associated with accelerated GFR decline in the general
middle-aged population. In persons using antihypertensive medication, elevated BP is associated with a paradoxical
slower GFR decline. Studies with even longer observation periods are needed to evaluate the ultimate effect of BP
on kidney function.
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Background
Hypertension is one of the most important causes of end-
stage renal disease [1–6]. However, it is not clear whether
hypertension also contributes to the gradual loss of kidney
function seen in the general population with increasing
age. The age-related decline in glomerular filtration rate
(GFR) is the most important predisposing cause of chronic
kidney disease (CKD) in old age, which affects 70% at
eighty years of age [7]. Several observational studies have
found an association between baseline blood pressure (BP)
and subsequent GFR decline or incident CKD, [8–14]. but
there are also studies that have shown no relationship or
even a higher GFR [15–20]. In a recent meta-analysis of
randomized controlled trials including 44,389 participants,
intensified antihypertensive treatment had no statistically
significant effect on the risk of end-stage renal disease [21].
Except in patients with diabetes or CKD, there is currently
no evidence from randomized controlled trials that antihy-
pertensive treatment or intensified antihypertensive treat-
ment lowers the risk of kidney dysfunction [22–25].
There are several possible explanations for the divergent
results of observational studies. One important explan-
ation could be that the great majority of these investiga-
tions have studied GFR decline as an effect of BP and
antihypertensive treatment at baseline. Since both BP and
treatment are dynamic parameters, they will change
during follow-up and exert a variable influence on GFR.
Because the effect of BP on GFR is commonly believed to
be continuous and not limited to a one-time baseline
event, this approach may give a distorted picture of the re-
lationship between them. To our knowledge, no previous
study of age-related GFR decline in the general population
has considered this issue. Additionally, previous studies
have relied on GFR estimated from creatinine or cystatin
C instead of actual measurements of GFR. These
estimates are known to be influenced by several non-GFR
factors that may have biased the results [26–28].
We have measured GFR as iohexol clearance in the
Renal Iohexol-clearance Survey in Tromsø 6 (RENIS-T6)
and again in the RENIS Follow-up Study (RENIS-FU)
after a median observation time of 5.6 years. Iohexol clear-
ance is recognized as a precise method for measuring
GFR [29]. As far as we know, this is the only study of age-
related GFR decline using GFR measurements. In a previ-
ous analysis, we found no association between baseline BP
and GFR decline [30]. In the present study, we investi-
gated the relationship between the GFR decline rate and
BP and antihypertensive treatment ascertained as time-
varying variables at both baseline and follow-up.
Methods
Study population
This study is a follow-up of RENIS-T6 which measured
baseline iohexol-clearance in 1627 people between 50
and 62 years of age between 2007 and 2009. We
included a representative sample of subjects from the
general population without self-reported kidney disease,
myocardial infarction, stroke or diabetes from the
municipality of Tromsø in Northern Norway, as previ-
ously described in detail [31]. In the present study, we
excluded 33 subjects who satisfied biochemical criteria
for diabetes (fasting glucose ≥ 7.0 mmol/L and/or hemo-
globin A1c ≥ 6.5%) at baseline, leaving 1594 subjects.
Ten subjects with missing data for baseline hemoglobin
A1c who all had fasting glucose < 7.0 mmol/L, were not
excluded. Follow-up measurements of GFR in RENIS-FU
were performed between September 2013 and January
2015. All the participants of the baseline study were
invited except for 23 subjects who had died and 7 who
had suffered a possible delayed allergic reaction to iohexol,
leading to 1564 total people eligible (Fig. 1). A random
sample of 5% was invited to a repeated follow-up
GFR measurement to obtain a group of subjects with
three GFR measurements, which is necessary for
analysis with a linear mixed regression model with
random intercept and slope and an unstructured
covariance matrix [32].
Fig. 1 Inclusion of subjects in the RENIS follow-up study (RENIS-FU)
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This study complied with the Declaration of Helsinki
and was approved by the Norwegian Data Inspectorate
and the Regional Committee for Medical and Health
Research Ethics of North Norway. All subjects provided
written consent. All procedures were in accordance with
institutional guidelines.
Data
Both RENIS-T6 and RENIS-FU were conducted in the
Clinical Research Unit at the University Hospital of
North Norway. A health questionnaire with questions
about alcohol and tobacco use and all current medica-
tions was administered on both occasions. Tobacco use
was coded as the number of cigarettes currently smoked
daily. Alcohol use was coded as 1 for the use of alcohol
more than once a week and 0 otherwise.
Measurements
Iohexol clearance
Baseline and follow-up GFR were measured using
single-sample plasma clearance of iohexol, which has
been validated against gold standard methods [33–36].
RENIS-FU used the same procedure as in the baseline
RENIS-T6, which has previously been described in
detail [30, 31].
A 6% random sample of blood samples from the base-
line investigation previously frozen at −80 °C were
thawed and reanalyzed to adjust for a possible drift in
the method between baseline and follow-up. The mean
difference in the GFR between follow-up and baseline
was 2.28 mL/min/1.73 m2. All baseline GFR measure-
ments reported in this study were adjusted by adding
this constant to the original measurements, as described
previously [30].
A total of 87 subjects had a repeated follow-up meas-
urement of GFR. The mean coefficient of variation (95%
confidence interval) for the intra-individual GFR vari-
ation was 4.2% (3.4–4.9%) [30]. The repeated follow-up
measurements was performed a median (interquartile
range (IQR)) of 35 (22–49) days after the first.
Blood pressure measurements
Attended BP measurements were performed by trained
study nurses in the seated position after 2 min rest using an
automated device and the appropriate cuff size (model UA
799; A&D, Tokyo, Japan). BP was measured three times
with 1 min between measurements. The average of the sec-
ond and the third measurement was used in the analyses.
Hypertension was defined as systolic BP (SBP) ≥ 140 mmHg,
diastolic BP (DBP) ≥ 90 mmHg or the use of antihyperten-
sive medication. Mean pulse pressure (PP) was defined as
SBP minus DBP and mean arterial pressure (MAP) as DBP
plus one-third of the PP.
Other measurements
Fasting serum glucose, creatinine, cystatin C, triglycer-
ides, and LDL- and HDL-cholesterol, hemoglobin A1C
and the urine albumin-creatinine ratio (ACR) were mea-
sured with standard methods as described previously
[37, 38]. Serum creatinine was measured using an
enzymatic assay standardized to the isotope dilution mass
spectroscopy method (CREA Plus, Roche Diagnostics,
GmbH, Mannheim, Germany). Cystatin C was measured by
a particle-enhanced turbidimetric immunoassay (Gentian,
Moss, Norway) and calibrated to the international
reference ERM-DA471/IFCC as previously described [39].
Estimated GFR (eGFR) was calculated from creatinine or
cystatin C using the Chronic Kidney Disease Epidemiology
Collaboration equations (eGFRcrea and eGFRcys) [40].
Statistical methods
Mean (standard deviation (SD)) or median (IQR) for
skewed variables were used for descriptive statistics.
Differences between baseline and follow-up were tested
with the paired t-test or Wilcoxon signed-rank test for
continuous variables and McNemar’s test for paired
dichotomous variables.
The GFR measurements were analyzed in linear mixed
models with random intercept and slope [32, 41]. All of
the subjects included in the baseline RENIS cohort were
included in the linear mixed regression analyses regardless
of whether they were examined at follow-up because linear
mixed models allow for missing observations at one or
more points in time [41, 42]. The subjects had from one to
three GFR measurements: baseline (n = 1594), follow-up
(n = 1299) and/or repeated follow-up (n = 87). Absolute
GFR in mL/min was used as the dependent variable. Ob-
servation time from baseline was used as the independent
time variable. Associations between the BP components
(SBP, DBP, PP and MAP) and the rate of change in GFR
were estimated by including two-way interaction terms be-
tween the BP variable in question and the time variable.
Separate regression analyses were performed for each BP
component. The linear mixed regression used time-varying
values measured at both baseline and follow-up for all the
independent variables, including BP components, antihy-
pertensive treatment and adjustment variables.
The linear mixed regression analyses were adjusted for
baseline age, sex and the following two sets of time-
varying adjustment variables: Model 1 (body weight;
height; individual dichotomous variables for the use of
ACE-inhibitors, A2-receptor blockers, beta-blockers,
calcium-blockers, diuretics and other antihypertensives)
and model 2 (same variables as model 1 and also includ-
ing LDL-cholesterol, HDL-cholesterol, fasting triglycer-
ides, fasting glucose, ACR, pulse frequency, number of
cigarettes currently smoked, and a dichotomous variable
for the alcohol use).
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Non-linear effects of the BP components on the GFR
rate of change were explored by including second-
degree fractional polynomial transformations of the BP
components in the interactions with time in the linear
mixed regression models [43].
Subjects with missing data for alcohol use (n = 6),
ACR (n = 5) or triglycerides (n = 4) at baseline, and one
subject with missing data for alcohol use at follow-up
were excluded from the analyses. There were no missing
data for the other independent variables or for GFR.
The same linear mixed regression analyses as described
above were performed with change in estimated GFR
assessed by eGFRcrea or eGFRcys as the dependent
variables. Statistical significance was set at 0.05. All of the
statistical analyses were performed in STATA/MP 13.1
(www.stata.com).
Results
A total of 1299 (81%) of the 1594 participants in the
baseline cohort were investigated at follow-up after a
median (IQR) observation time of 5.63 years (5.23–6.03)
(Fig. 1). Most variables changed between baseline and
follow-up (Table 1). The percentage of subjects with
hypertension increased from 42 to 52 and the percentage
of subjects receiving antihypertensives from 18 to 31
between baseline and follow-up. There was a slight
increase in SBP and a slight reduction in DBP (p < 0.05).
Except for the percentage of current smokers (18 vs. 28,
p < 0.05), there were only small differences in baseline
characteristics between those included and those lost to
follow-up, as reported previously [30].
The unadjusted mean (SD) rate of change for the abso-
lute GFR in the study period was −0.95 (2.23) mL/min/year.
A negative change signifies a decline in GFR.
The absence of associations between baseline BP com-
ponents and the GFR decline rate has been reported
previously [30]. When analyzing time-varying BP with
adjustment for independent variables measured at both
baseline and follow-up; SBP, DBP and MAP, but not PP,
were positively associated with GFR change in separate
models, indicating slower GFR decline for higher BP
values (p < 0.05) (Table 2), i.e. that lowering of BP was
associated with a steeper GFR decline. Because time-
varying independent variables for antihypertensive medi-
cation were used, these associations were independent of
both the antihypertensive medication and changes in
medication use between baseline and follow-up.
There were no statistically significant non-linear
relationships between the BP components and GFR rate
of change.
There were statistically significant interactions between
a dichotomous time-varying variable for antihypertensive
treatment (yes/no) and SBP, DBP, and MAP respectively
in the fully adjusted models in Table 2 (p < 0.001). The
interactions indicate that the associations between GFR
decline and SBP, DBP and MAP were stronger when com-
bined with antihypertensive medication (Fig. 2).
We performed subgroup analyses for persons with
hypertension at baseline and/or follow-up, for persons
with normotension at both baseline and follow-up, for
persons without self-reported heart disease, for persons
without albuminuria (ACR less than 1.92 mg/mmol for
men and 2.83 mg/mmol for women) and for persons
with GFR greater than 60 ml/min/1.73 m2 (Additional
file 1: Tables S1 and S2). The results were numerically
similar to the main results in Table 2, but not statisti-
cally significant for SBP, DBP and MAP in the normo-
tensive subgroup.
The associations between BP components and GFR
decline assessed by body-surface adjusted GFR (GFRBSA)
and estimated GFR based on either creatinine or cystatin
C (eGFRcrea and eGFRcys) were analyzed (Additional file 1:
Table S3). The same models as in Table 2 were used.
There was no statistically significant relationship between
any of the BP components and eGFRcrea or eGFRcys. The
results for GFRBSA were similar to those for absolute GFR
in Table 2.
The regression models in Table 2 were re-analyzed with
the mean of baseline and follow-up values substituted for
the time-varying independent variables as predictors of
the GFR decline slope. The results were essentially the
same as in Table 2 (Additional file 1: Table S4).
Discussion
The results of this investigation do not support the hy-
pothesis that elevated BP causes accelerated age-related
GFR decline in the general population during almost
6 years of follow-up (Table 2). On the contrary, the ana-
lyses indicate an association of higher SBP, DBP and
MAP with a paradoxical slower GFR decline, i.e. that
improved BP was associated with a steeper decline.
There were statistically significant interactions between
the BP components and antihypertensive treatment, so
that the associations between BP and GFR decline oc-
curred primarily in patients treated with antihyperten-
sive agents (Fig. 2). The reason may be that GFR is more
sensitive to BP changes in treated persons because long-
standing hypertension or antihypertensive drugs inter-
fere with the autoregulation of glomerular blood flow
[44, 45]. This makes GFR more sensitive to changes in
BP, which manifested as a steeper GFR decline with
intensified BP treatment in our population.
In randomized controlled trials of antihypertensive
drugs in CKD patients, an initial drop in GFR is com-
monly observed when treatment is started, followed by a
subsequent slower decline [46, 47]. This finding has
been interpreted as a beneficial effect of reducing an
abnormally high GFR, so-called hyperfiltration [48].
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Table 1 Study population characteristics at baseline and follow-up. The RENIS-FU study
Baseline Follow-up P-value for differencea
N (%) 1594 1299
Male gender, n (%) 781 (49%) 643 (49%)
Age, years 58.1 (3.8) 63.6 (4.0)
Body mass index, kg/m2 27.2 (4.0) 27.1 (4.0) 0.59
Hypertensionb, n (%) 674 (42%) 672 (52%) <0.001
Systolic BP, mmHg 129.4 (17.5) 130.5 (16.9) 0.001
Diastolic BP, mmHg 83.4 (9.8) 81.9 (9.3) <0.001
Pulse pressure, mmHg 46.1 (11.4) 48.6 (12.2) <0.001
Mean arterial BP, mmHg 98.7 (11.7) 98.1 (10.9) 0.08
Pulse frequency, beats/min 66.6 (9.8) 64.5 (9.2) <0.001
Antihypertensive medication, n (%) 289 (18%) 405 (31%) <0.001
ACE inhibitor, n (%) 28 (1.8%) 48 (3.7%) <0.001
A2 blocker, n (%) 132 (8.3%) 201 (15.5%) <0.001
Betablocker, n (%) 67 (4.2%) 93 (7.2%) <0.001
Calcium blocker, n (%) 80 (5.0%) 126 (9.7%) <0.001
Diuretic, n (%) 140 (8.8%) 203 (15.6%) <0.001
Other antihypertenives, n (%) 1 (0.1%) 5 (0.4%) 0.06
Current smoker, n (%) 322 (20%) 173 (13%) <0.001
Use of alcohol more than 2–4 times a month, n (%) 434 (27%) 431 (33%) 0.01
LDL cholesterol, mmol/L 3.67 (0.86) 3.58 (0.90) <0.001
HDL cholesterol, mmol/L 1.54 (0.42) 1.63 (0.46) <0.001
Fasting triglycerides, mmol/L 1.00 (0.80 to 1.50) 1.00 (0.80 to 1.30) 0.12
Fasting glucose, mmol/L 5.30 (5.00 to 5.60) 5.40 (5.10 to 5.80) <0.001
Urinary albumin-creatinine ratio, mg/mmol 0.23 (0.10 to 0.54) 0.34 (0.10 to 0.58) <0.001
Absolute GFR, mL/min 103.8 (19.9) 98.2 (19.8) <0.001
GFR, mL/min/1.73 m2 93.8 (14.3) 88.9 (14.5) <0.001
Estimates are given as mean (standard deviation), median (interquartile range) or percent
Abbreviations: RENIS-FU Study the Renal Iohexol-clearance Survey Follow-up Study, HDL high-density lipoprotein, LDL low-density lipoprotein, BP blood pressure,
GFR glomerular filtration rate
aPaired statistical tests for those who participated both at baseline and follow-up
bSystolic BP > = 140, diastolic BP > = 90 or antihypertensive medication
Table 2 The associations between time-varying blood pressure and GFR change rates in linear mixed regression analyses. The
RENIS-FU study
BP component Model 1a Model 2b
Beta (mL/min/year) 95% confidence interval P-value Beta (mL/min/year) 95% confidence interval P-value
Systolic BP per 10 mmHg 0.09 0.02 to 0.17 0.02 0.10‡ 0.02 to 0.18 0.02
Diastolic BP per 10 mmHg 0.16 0.02 to 0.30 0.03 0.20§ 0.05 to 0.34 0.01
Pulse pressure per 10 mmHg 0.08 -0.03 to 0.19 0.15 0.07 -0.04 to 0.18 0.21
Mean arterial pressure per 10 mmHg 0.15 0.03 to 0.27 0.01 0.17|| 0.05 to 0.30 0.007
Each horizontal section in the table corresponds to one linear mixed regression model. Negative coefficients indicate a steeper GFR decline; positive coefficients a
slower decline. The models used time-varying independent variables measured at both baseline and follow-up
Abbreviations: RENIS-FU Study the Renal Iohexol-clearance Survey Follow-up Study, BP blood pressure
aModel 1 adjusted for age; sex; body weight; height; individual dichotomous variables for the use of ACE-inhibitors, A2-receptor blockers, beta-blockers, calcium-blockers,
diuretics and other antihypertensives
bAdjusted as model 1 and in addition LDL-cholesterol, HDL-cholesterol, fasting triglycerides, fasting glucose, urinary ACR, pulse frequency, number of cigarettes
currently smoked, a dichotomous variable for the weekly use of alcohol or not
‡P < 0.001 for the interaction between systolic BP and the use of any antihypertensive medication. Beta = 0.01 without and 0.33 mL/min/year/10 mmHg with
antihypertensive medication
§P = 0.001 for the interaction between diastolic BP and the use of any antihypertensive medication. Beta = 0.09 without and 0.42 mL/min/year/10 mmHg with
antihypertensive medication
||P < 0.001 for the interaction between mean arterial pressure and the use of any antihypertensive medication. Beta = 0.05 without and 0.49 mL/min/year/
10 mmHg with antihypertensive medication
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Hyperfiltration is thought to be the first step in a se-
quence of events leading to reduced GFR and CKD [49].
However, there is also evidence of a longer-term drop in
estimated GFR after intensive antihypertensive treat-
ment, recently seen in two randomized trials with
median follow-up of three years [24, 25]. Although our
study population differs in several respects from the pa-
tients in these studies, our results suggest that the phase
of reduced GFR due to an improvement of hyperfiltra-
tion may last longer than previously thought. This may
explain the lack of effect on renal endpoint in trials with
follow-up ranging from 1 to 7 years [22, 23].
To our knowledge, the present study is the first to as-
sess the association between BP and GFR decline in the
general population using measurements rather than esti-
mates of GFR. Studies that have used serum creatinine,
estimated GFR, or creatinine clearance have given mixed
results [8–14, 50]. We found no statistically significant
associations between BP and the change rates of
estimated GFR based on creatinine and/or cystatin C
(Additional file 1: Table S3). The reason may have been
the influence of non-GFR factors on creatinine and
cystatin C or the low precision of estimated GFR in the
normal range [26–28]. To our knowledge, only one pre-
vious study of GFR decline has used time-varying BP in
a non-CKD population [51]. Vupputuri et al. found an
association between increased time-varying BP and rapid
GFR decline. However, the study was not population-
based, it used estimated GFR from creatinine and did
not adjust for changes in antihypertensive medication. In
the general population, we are not aware of any previous
study that has adjusted for individual classes of
Fig. 2 Associations between blood pressure components and GFR change rates in linear mixed models with time-varying independent variables.
Separate curves for marginal GFR change rates with and without antihypertensive medication are shown (p < 0.05 for the interaction with
antihypertensive medication for each blood pressure component). Dashed lines indicate 95% confidence intervals. Each curve should be interpreted as
giving the marginal GFR change rate for a person with constant antihypertensive medication and BP component throughout the study period. The
analyses were adjusted using time-varying variables for age, sex, body weight, height, LDL-cholesterol, HDL-cholesterol, fasting triglycerides, fasting
glucose, urinary ACR, pulse frequency, number of cigarettes currently smoked, and a dichotomous variable for the weekly use of alcohol. The
distribution of each blood pressure component is superimposed on each graph
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antihypertensive medications or included time-varying
adjustment variables. The considerable changes observed
in both antihypertensive medication and hypertension
status during the follow-up in our study underlines the
importance of using statistical models that do not rely
solely on baseline variables.
The finding of an association between higher BP and a
slower GFR decline seems to be inconsistent with
observational studies that have found hypertension a risk
factor for both ESRD [1, 2, 5]. and less severe CKD [52–57].
One possible explanation is that additional genetic or
environmental factors may lead to the development of
progressive kidney disease in susceptible patients only.
Another possibility is that renal hyperfiltration may be the
first stage of hypertensive nephropathy, similar to the
hyperfiltration phase of diabetic nephropathy. We mea-
sured whole kidney GFR which is a function of the total
number of nephrons and single nephron GFR. Other
studies have found a reduced nephron number in subjects
with hypertension [58–60]. If we conservatively assume an
average rate of age-related loss of nephrons in hyperten-
sive subjects, a slower than average decline in whole kid-
ney GFR implies an increasing single nephron GFR in the
remaining nephrons. This means that our findings most
likely reflect an elevated GFR or hyperfiltration at the
single nephron level. Other studies have also found cross-
sectional associations between elevated BP and hyperfil-
tration both in hypertensive patients [15–18]. and in the
general population [19].
Conditions with both low BP and low GFR, such as
advanced heart failure and serious infections, could pos-
sibly confound the association between low BP and a
faster GFR decline, but are unlikely to explain the find-
ings in this relatively healthy, ambulatory cohort. Only
subjects without cardiovascular disease at baseline were
included, and an analysis after excluding subjects with
self-reported heart disease at follow-up made essentially
the same findings as in the main analysis (Additional
file 1: Table S1). We rescheduled GFR measurements
for subjects with acute infections.
The principal strength of the present study is the use
of measured GFR rather than estimated GFR from
creatinine or cystatin C. When we repeated the analyses
with estimated GFR instead of iohexol clearance, the
regression coefficients were attenuated and not statisti-
cally significant (Additional file 1: Table S3). We limited
confounding from comorbid conditions by excluding
subjects with diabetes or cardiovascular disease at base-
line. Because a third GFR measurement was obtained
from a random subset of subjects, state-of-the-art linear
mixed models rather than ordinary linear regression
could be used for the analyses [61].
The most important limitation of our investigation
was that conclusions about causality cannot be drawn
from an observational study. In particular, the use of
time-varying variables in the regression analyses does
not allow us to establish the temporal precedence of ele-
vated BP relative to a change in GFR decline, and can
only demonstrate an association between these variables.
The direction of causality is also uncertain, as subclinical
renal damage has been suggested as a possible cause of
primary hypertension [62]. In addition, the time varying
variables were only ascertained at baseline and follow-up.
More frequent measurements during follow-up would
have given a more detailed picture of the relationship
between BP and GFR and more precise estimates of
effects, but would probably not have changed the overall
conclusions or our study. Only middle-aged Caucasians
were included and caution should be exercised when
generalizing the results to other age groups and
ethnic groups.
Conclusions
We conclude that higher BP is not associated with an
accelerated mean age-related GFR decline in the general
population, but that lower BP because of antihyperten-
sive treatment is associated with a medium-term steeper
GFR decline. This finding is still consistent with a long-
term beneficial effect of antihypertensive treatment on
GFR decline, but indicates that a possible long term
slowing effect on the decline may be preceded by a
phase of reduced hyperfiltration of longer duration than
previously thought. This should be investigated in stud-
ies with longer follow-up and repeated measurements of
GFR. In primary hypertension, randomized controlled
trials of the effect of antihypertensive treatment on renal
endpoints should employ substantially longer follow-up
than in previous trials.
Additional file
Additional file 1: Four additional tables (Table S1-S4.) (DOCX 43 kb)
Abbreviations
ACR: Albumin creatinine ratio; BP: Blood pressure; CKD: Chronic kidney
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